Fundus Autofluorescence in Type 2 Idiopathic Macular Telangiectasia: Correlation with Optical Coherence Tomography and Microperimetry
Overview
Authors
Affiliations
Purpose: To use multiple imaging methods to investigate patients with type 2 idiopathic macular telangiectasia (IMT) at different disease severity stages so as to characterize and categorize disease progression through the full spectrum of disease phenotypes.
Design: Observational case series.
Methods: Twelve patients with type 2 IMT (22 eyes) examined with fundus photography, angiography, optical coherence tomography imaging, fundus autofluorescence (FAF), and microperimetry testing in an institutional setting.
Results: Eyes examined by multiple imaging methods were classified into 5 proposed categories (0 through 4): category 0 (fellow) eyes had normal results on all imaging methods. Category 1 eyes had increased foveal autofluorescence on FAF imaging as the only imaging abnormality. Category 2 eyes had increased foveal autofluorescence together with funduscopic and angiographic features typical of type 2 IMT. Category 3 eyes had additional evidence of foveal atrophy on optical coherence tomography, and category 4 eyes had all the above features plus clinically evident pigment clumping. FAF signal increased in intensity in the foveal region from category 0 through category 3, whereas category 4 eyes demonstrated a mixed pattern of increased and decreased FAF signal.
Conclusions: The findings here outline a sequence of progressive changes seen with multiple imaging methods in advancing stages of disease. Increase in foveal autofluorescence is an early anatomic change in type 2 IMT that may precede typical clinical and angiographic changes. Loss of macular pigment density in the fovea and a changing composition of fluorophores in the retinal pigment epithelium may underlie these changes on FAF in the fundus.
High-Resolution Imaging in Macular Telangiectasia Type 2: Case Series and Literature Review.
Mirescu A, Balta F, Barac R, Deleanu D, Tofolean I, Balta G Diagnostics (Basel). 2024; 14(13).
PMID: 39001242 PMC: 11241511. DOI: 10.3390/diagnostics14131351.
Chandran K, Giridhar A, Desai S, Gopalakrishnan M, Indu V, Sivaprasad S Indian J Ophthalmol. 2023; 72(Suppl 1):S125-S134.
PMID: 38131554 PMC: 10833168. DOI: 10.4103/IJO.IJO_78_23.
A complete clinical review of idiopathic macular telangiectasia.
Jayasri P, Stephen A Oman J Ophthalmol. 2023; 16(3):421-426.
PMID: 38059108 PMC: 10697264. DOI: 10.4103/ojo.ojo_170_22.
Is Type 2 Macular Telangiectasia a Bilateral and Symmetrical Disease Entity?.
Venkatesh R, Nahata H, Reddy N, Mishra P, Mangla R, Yadav N J Curr Ophthalmol. 2023; 34(4):428-435.
PMID: 37180535 PMC: 10170975. DOI: 10.4103/joco.joco_68_22.
Macular Telangiectasia Type 2: A Comprehensive Review.
Kedarisetti K, Narayanan R, Stewart M, Reddy Gurram N, Khanani A Clin Ophthalmol. 2022; 16:3297-3309.
PMID: 36237488 PMC: 9553319. DOI: 10.2147/OPTH.S373538.